Perioral Dermatitis Treatment Guidelines

Systemic Antibiotic Selection

The American Academy of Dermatology recommends oral tetracyclines as first-line systemic therapy for perioral dermatitis in adults and children over 8 years, as they significantly shorten time to papule resolution compared to other options 1, 2
Tetracyclines must be combined with topical benzoyl peroxide or a retinoid to prevent bacterial resistance, and their use should be limited to 3-4 months maximum 1, 2
The American Academy of Dermatology advises against using tetracyclines in pregnancy, nursing women, and children under 8 years due to tooth staining 1, 3, 4
Azithromycin is a reasonable second-line oral antibiotic for perioral dermatitis, particularly in children under 8 years who cannot take tetracyclines 1, 2

The FDA warns that oral azithromycin may cause QT prolongation, arrhythmias, and torsades de pointes, with increased cardiovascular death risk in patients with high baseline cardiovascular disease risk 3, 4, 2, 5
Screening for cardiovascular risk factors is recommended before prescribing azithromycin 3, 4, 5

Re-evaluation at 3-4 months is recommended if using systemic antibiotics to minimize bacterial resistance development 1, 2
Transition to topical maintenance therapy (retinoid or benzoyl peroxide) is advised after systemic antibiotic completion 1, 2

The American Academy of Dermatology recommends never using azithromycin as monotherapy, but rather combining it with topical benzoyl peroxide or retinoid to prevent bacterial resistance 1, 2
Avoid prescribing tetracyclines in children under 8 years, pregnant women, or nursing mothers 1, 3, 4
Cardiovascular screening before azithromycin use is crucial, especially in patients with baseline cardiac risk 3, 4, 2, 5

The American Academy of Dermatology warns that azithromycin can prolong the QT interval, precipitate ventricular arrhythmias (including torsades de pointes), and increase cardiovascular mortality in patients who already have cardiovascular disease. 6

Prior to prescribing azithromycin, clinicians should screen patients for a history of arrhythmias, documented QT‑interval prolongation, electrolyte disturbances such as low potassium or magnesium, concurrent use of other QT‑prolonging drugs, and structural heart disease. This screening is essential to mitigate the drug’s cardiac risks. 6

Azithromycin is contraindicated in individuals who have previously experienced cholestatic jaundice or hepatic dysfunction that was attributed to azithromycin use. 6